What happened
In a midstage study, Insilico Medicine’s drug rentosertib reduced biological age, measured by six aging clocks, per an analysis in Nature Biotechnology. Placebo recipients saw little change.
Why it matters
The result suggests an AI-discovered lung drug may reverse aging markers, not just treat disease, a new potential use. The company is Hong Kong-listed.
What to watch
Whether the early results hold in larger, longer studies; the analysis included only 42 patients with chronic lung disease. CEO Alex Zhavoronkov cautioned the long-term health effects are unknown.
WHO IT HITSPatients with chronic lung disease and researchers studying aging could be affected, as the drug shows potential beyond its original purpose. Insilico Medicine and its investors also face the outcome of further trials.
Ask the AI about this article →
Summaries like this, in your inbox every morning.
The study marks a step for AI-discovered drugs, showing a lung disease treatment may also affect biological aging. Insilico Medicine, listed in Hong Kong, published the analysis in Nature Biotechnology.
Rentosertib reduced biological age across six aging clocks in a midstage trial with 42 patients. This suggests the drug might have broader uses, though the mechanism linking lung disease and aging is not detailed.
The results are early, and the long-term health effects are unknown. The company's CEO, Alex Zhavoronkov, cautions that larger studies are needed, so the potential for broader use hinges on further validation.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Palantir has chosen Nebius as its preferred sovereign AI infrastructure partner, bringing Nebius computation a…
Mistral raised €3 billion in Series D funding, reaching a post-money valuation of more than €21 billion
Maggie Appleton explains how generative AI like ChatGPT and image generators will expand the web's 'dark fores…
OpenAI's internal report says its coding agents now run 3.1 workdays for every human workday in its research o…
Insilico Medicine published an exploratory analysis in Nature Biotechnology showing rentosertib shifted blood…
Danijar Hafner, who left Google DeepMind in the fall of 2025, is building a stealth startup that uses humanoid…
